EU/3/15/1531

About

On 28 July 2015, orphan designation (EU/3/15/1531) was granted by the European Commission to Newron Pharmaceuticals SpA, Italy, for sarizotan hydrochloride for the treatment of Rett syndrome.

Key facts

Active substance
Sarizotan hydrochloride
Disease / condition
Treatment of Rett syndrome
Date of first decision
28/07/2015
Outcome
Positive
EU designation number
EU/3/15/1531

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Newron Pharmaceuticals SpA
Via Lodovico Aristo
20091 Bresso
Milan
Italy
Tel. +39 0261034622
Fax +39 0261034654 or +39 0261034655
E-mail: info@newron.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating